non metastatic breast cancer, HR
Showing 1 - 25 of >10,000
Among HR+/HER2- Advanced or Metastatic Breast Cancer in France
Recruiting
- Breast Cancer
- ribociclib + ET
-
La Roche sur Yon Cedex, FranceNovartis Investigative Site
Jan 16, 2023
Luminal Metastatic breAst caNcer in Real-life Clinical pracTice
Completed
- HR+/HER2- Breast Cancer
- +2 more
-
Moscow, Russian FederationRussian Society of Clinical Oncology
Mar 29, 2023
Breast Cancer Patients Diagnosed With HR+/HER2- Locally Advanced
Active, not recruiting
- Breast Cancer
-
Copenhagen, DenmarkDanish Breast Cancer Group
Jul 6, 2022
Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer Trial (BGB-43395, Fulvestrant, Letrozole)
Not yet recruiting
- Advanced Solid Tumor
- +8 more
- BGB-43395
- +2 more
- (no location specified)
Nov 13, 2023
Patterns & Clinical Outcomes of Palbociclib Combinations in
Recruiting
- Metastatic Breast Cancer
-
Cairo, Egypt
- +7 more
Nov 8, 2022
Metastatic Breast Cancer Trial in Spain (Pembrolizumab, Paclitaxel)
Active, not recruiting
- Metastatic Breast Cancer
-
Hospitalet de Llobregat, Barcelona, Spain
- +6 more
Jan 23, 2023
A NIS of Alpelisib in Combination With Fulvestrant in
Not yet recruiting
- Hormone Receptor Positive HER2 Negative Breast Cancer With a PIK3CA Mutation
- Alpelisib
- Fulvestrant
- (no location specified)
Aug 9, 2022
Advanced Breast Cancer, Metastatic Breast Cancer, Breast Cancer Trial in United States (NUV-422, Fulvestrant)
Recruiting
- Advanced Breast Cancer
- +7 more
-
Anaheim, California
- +4 more
Apr 6, 2022
Invasive Mammary Carcinoma, Metastatic Breast Cancer Trial in Nashville (Capecitabine, Endocrine-therapy, MammoPrint ® and
Not yet recruiting
- Invasive Mammary Carcinoma
- Metastatic Breast Cancer
- Capecitabine
- +2 more
-
Nashville, TennesseeVanderbilt University/Ingram Cancer Center
Jan 11, 2023
Treatment Patterns of HR+/HER2- Advanced or Metastatic Breast
Completed
- HR+/HER2- Advanced or Metastatic Breast Cancer
-
Dublin, IrelandNovartis Pharmaceuticals
May 2, 2023
Metastatic Breast Cancer, Unresectable Breast Cancer Trial in Saint Louis (DiviTum® TKa assay, CDK4/6 + Endocrine therapy)
Not yet recruiting
- Metastatic Breast Cancer
- Unresectable Breast Cancer
- DiviTum® TKa assay
- CDK4/6 + Endocrine therapy
-
Saint Louis, MissouriWashington University School of Medicine
Jul 27, 2023
Ribociclib in Combination With Hormonal Therapy in HR+/HER2-
Not yet recruiting
- Breast Cancer
- ribociclib
- (no location specified)
Oct 10, 2023
Compare Overall Survival in Medicare Metastatic Breast Cancer
Active, not recruiting
- Breast Cancer
- Palbociclib
- Aromatase Inhibitor
-
New York, New YorkPfizer New York
Oct 11, 2023
Learn About Use and Effects of CDK4/6 Inhibitors in Canadian
Active, not recruiting
- Breast Cancer
-
Kirkland, Quebec, CanadaPfizer Canada
Mar 5, 2023
Breast Cancer Trial (Disitamab Vedotin+Anlotinib)
Not yet recruiting
- Breast Cancer
- Disitamab Vedotin+Anlotinib
- (no location specified)
Aug 14, 2023
Breast Cancer Trial in Chengdu (Dalpiciclib combined with Letrozole)
Not yet recruiting
- Breast Cancer
- Dalpiciclib combined with Letrozole
-
Chengdu, Sichuan, ChinaWest China Hospital, Sichuan University
Aug 3, 2023
CDK4/6 Inhibitors Combined With Endocrine Therapy and Subsequent
Not yet recruiting
- Breast Cancer
- +3 more
- Different treatment regimens following progression on CDK4/6 inhibitors.
- (no location specified)
Sep 5, 2023
Brain Metastases, HR+ Metastatic Breast Cancer Trial in Tampa (Stereotactic Radiosurgery (SRS), Abemaciclib, Endocrine therapy)
Recruiting
- Brain Metastases
- HR+ Metastatic Breast Cancer
- Stereotactic Radiosurgery (SRS)
- +2 more
-
Tampa, FloridaMoffitt Cancer Center
Nov 1, 2022
Breast Cancer, Metastatic Breast Cancer, Hormone Receptor Positive Breast Carcinoma Trial in Washington, Baltimore, Hackensack
Active, not recruiting
- Breast Cancer
- +2 more
-
Washington, District of Columbia
- +4 more
Jan 31, 2023
Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed Trial in Hangzhou (dalpiciclib;
Recruiting
- Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed
- dalpiciclib; fluvestrant; compound gossypol acetate tablets
-
Hangzhou, Zhejiang, ChinazhejiangCH
Nov 9, 2023
Breast Cancer Trial in Shanghai (Dalpiciclib, Fulvestrant, Pertuzumab)
Active, not recruiting
- Breast Cancer
- Dalpiciclib
- +3 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Oct 10, 2022